Iovance Biotherapeutics reported early pilot trial results for lifileucel in aggressive soft tissue sarcomas. The company plans to start a registrational trial and seek expedited FDA approval based on ...

Synovial sarcoma, a rare cancer, thrives on glutamine. Blocking its nutrient supply with the drug V9302 stops tumor growth, offering a new way to treat the disease.

Results presented here showed negative pressure wound therapy is a safe adjunct for soft tissue sarcoma treated with ...

Iovance Biotherapeutics Inc. IOVA stock is trading higher on Friday, with no news to justify the movement. Investors should ...

The newly-added diseases include skin cancer, mesothelioma, soft-tissue sarcoma and pharynx cancers, putting the total number ...

More than 400 cartons of Nilotinib capsules were voluntarily recalled by Cipla USA after failing manufacturing specifications ...

When Jon and Dayla Culp received the news that their six-year-old Labrador retriever, Clarice, had a malignant tumor near her ...

Pediatric sarcomas are a significant category within pediatric malignancies, comprising over 20% of solid malignant cancers in children. These cancers are ...

British Columbia has expanded its compensation coverage for firefighters in the province by adding eight cancers to the list ...

(Alliance News) - Faron Pharmaceuticals Ltd shares rose over 14% on Wednesday after the Turku, Finland-based biopharma's chief executive officer said the company is in "in-depth commercial discussions ...

Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company ...

Equity-Insider.com News Commentary -- The five-year cancer survival rate in the United States has reached a record 70%, reflecting decades of progress in early detection, targeted therapy, and ...